DOP2024000016A - Proteínas actrii y usos de las mismas - Google Patents

Proteínas actrii y usos de las mismas

Info

Publication number
DOP2024000016A
DOP2024000016A DO2024000016A DO2024000016A DOP2024000016A DO P2024000016 A DOP2024000016 A DO P2024000016A DO 2024000016 A DO2024000016 A DO 2024000016A DO 2024000016 A DO2024000016 A DO 2024000016A DO P2024000016 A DOP2024000016 A DO P2024000016A
Authority
DO
Dominican Republic
Prior art keywords
telangiectasia
risk
effective amount
therapeutically effective
patient receiving
Prior art date
Application number
DO2024000016A
Other languages
English (en)
Spanish (es)
Inventor
De Oliveira Pena Janethe
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of DOP2024000016A publication Critical patent/DOP2024000016A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DO2024000016A 2021-07-19 2024-01-18 Proteínas actrii y usos de las mismas DOP2024000016A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163223265P 2021-07-19 2021-07-19
PCT/US2022/037479 WO2023003815A1 (en) 2021-07-19 2022-07-18 Actrii proteins and uses thereof

Publications (1)

Publication Number Publication Date
DOP2024000016A true DOP2024000016A (es) 2024-06-16

Family

ID=84979535

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2024000016A DOP2024000016A (es) 2021-07-19 2024-01-18 Proteínas actrii y usos de las mismas

Country Status (18)

Country Link
US (1) US20240327494A1 (https=)
EP (1) EP4373577A4 (https=)
JP (1) JP2024526820A (https=)
KR (1) KR20240049857A (https=)
CN (1) CN117957014A (https=)
AU (1) AU2022316103A1 (https=)
CA (1) CA3225613A1 (https=)
CL (1) CL2024000151A1 (https=)
CO (1) CO2024001551A2 (https=)
CR (1) CR20240061A (https=)
DO (1) DOP2024000016A (https=)
EC (1) ECSP24012819A (https=)
GE (1) GEAP202416461A (https=)
IL (1) IL310141A (https=)
JO (1) JOP20240010A1 (https=)
MX (1) MX2024000829A (https=)
PE (1) PE20240777A1 (https=)
WO (1) WO2023003815A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
IL296394A (en) 2020-03-20 2022-11-01 Keros Therapeutics Inc Type ii activin receptor chimeras and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180055822A1 (en) * 2015-03-13 2018-03-01 Repoceuticals Aps Melatonin for Preventing and Treating Radiation Cystitis
CA3005975A1 (en) * 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
HRP20210694T1 (hr) * 2016-07-15 2021-09-17 Acceleron Pharma, Inc. Pripravci koji sadrže actriia polipeptide za uporabu za liječenje plućne hipertenzije

Also Published As

Publication number Publication date
CR20240061A (es) 2024-05-02
EP4373577A4 (en) 2025-05-14
CL2024000151A1 (es) 2024-08-09
JP2024526820A (ja) 2024-07-19
CA3225613A1 (en) 2023-01-26
WO2023003815A9 (en) 2023-05-11
KR20240049857A (ko) 2024-04-17
PE20240777A1 (es) 2024-04-17
IL310141A (en) 2024-03-01
WO2023003815A1 (en) 2023-01-26
AU2022316103A1 (en) 2024-02-08
EP4373577A1 (en) 2024-05-29
ECSP24012819A (es) 2024-03-01
US20240327494A1 (en) 2024-10-03
GEAP202416461A (en) 2024-04-25
JOP20240010A1 (ar) 2024-01-18
MX2024000829A (es) 2024-04-12
CO2024001551A2 (es) 2024-03-07
CN117957014A (zh) 2024-04-30

Similar Documents

Publication Publication Date Title
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
DOP2024000016A (es) Proteínas actrii y usos de las mismas
MX2022010774A (es) Composiciones que comprenden aminoacidos para su uso en el tratamiento de enfermedades relacionadas con la disfuncion mitocondrial.
AR058838A1 (es) Metodo para tratar el dano articular
BR112014021653A2 (pt) Formulação tópica, método para tratamento de feridas e método para fabricar uma formulação tópica
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22
PE20212158A1 (es) Composicion farmaceutica acuosa de anticuerpo anti-il17a y su uso
PE20250835A1 (es) Composiciones y uso de la tirzepatida
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CL2021001830A1 (es) Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa
BR112022004941A2 (pt) Métodos para tratar doenças autoimunes com o uso de antagonistas de interleucina-17 (il-17)
AR115883A1 (es) Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción
AR104721A1 (es) Fragmento fab anti-ngf humano
EA201792314A1 (ru) Фармацевтическая комбинация эверолимуса и дактолисиба
DOP2025000170A (es) Proteínas de fusión fc de il-12
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
CO2022000211A2 (es) Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad
CU20160194A7 (es) Composición vacunal que comprende un mutante de la interleucina-15 humana